Sangeeta Bhatia - Vertex Pharmaceuticals Director
| VRTX Stock | USD 393.10 1.07 0.27% |
Director
Dr. Sangeeta N. Bhatia, M.D., Ph.D. is Independent Director of Vertex Pharmaceuticals Incorporated. Dr. Bhatia is a professor at the Massachusetts Institute of Technology, or MIT, where she currently serves as the John J. and Dorothy Wilson Professor of Health Sciences TechnologyElectrical Engineering Computer Science. For the 2018 year, Dr. Bhatia was on sabbatical from MIT while she served as a cofounder of Glympse Bio, a private company focused on developing in vivo sensing technology dedicated to disease monitoring. Prior to joining MIT in 2005, Dr. Bhatia was a professor of bioengineering and medicine at the University of California at San Diego from 1998 through 2005. Dr. Bhatia also is an investigator for the Howard Hughes Medical Institute, a member of the Department of Medicine at Brigham and Womens Hospital, a member of the Broad Institute and a member of the Koch Institute for Integrative Cancer Research since 2015.
| Age | 49 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Address | 50 Northern Avenue, Boston, MA, United States, 02210 |
| Phone | 617 341 6100 |
| Web | https://www.vrtx.com |
Vertex Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of 0.1317 % which means that it generated a profit of $0.1317 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.2299 %, meaning that it created $0.2299 on every $100 dollars invested by stockholders. Vertex Pharmaceuticals' management efficiency ratios could be used to measure how well Vertex Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.18 in 2024. Return On Capital Employed is likely to rise to 0.21 in 2024. At this time, Vertex Pharmaceuticals' Return On Assets are fairly stable compared to the past year.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| David Scadden | Editas Medicine | 65 | |
| Sirisak Piyathatsikun | Ginkgo Bioworks Holdings | 42 | |
| JeanFrancois Formela | Intellia Therapeutics | 61 | |
| Marsha Fanucci | Alnylam Pharmaceuticals | 64 | |
| Kathy Rouan | Viking Therapeutics | 56 | |
| Charles Rowland | Viking Therapeutics | 59 | |
| Paul Amatavivadhana | Ginkgo Bioworks Holdings | N/A | |
| David Pyott | Alnylam Pharmaceuticals | 65 | |
| Steven Paul | Alnylam Pharmaceuticals | 67 | |
| Pablo Cagnoni | Crispr Therapeutics AG | 55 | |
| Simeon George | Crispr Therapeutics AG | 41 | |
| Claude Nicaise | Sarepta Therapeutics | 65 | |
| Somkiat Chuasiriphatthana | Ginkgo Bioworks Holdings | N/A | |
| Carl Gordon | Intellia Therapeutics | 52 | |
| Anthony Chase | Sarepta Therapeutics | 60 | |
| Michael Grey | Biomarin Pharmaceutical | 65 | |
| Ronald Renaud | PTC Therapeutics | 45 | |
| Stephen Webster | Viking Therapeutics | 57 | |
| Nancy Phelan | Moderna | 48 | |
| Adam Koppel | PTC Therapeutics | 45 | |
| Margaret Hamburg | Alnylam Pharmaceuticals | 62 | |
Management Performance
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.13 |
Vertex Pharmaceuticals Leadership Team
Elected by the shareholders, the Vertex Pharmaceuticals' board of directors comprises two types of representatives: Vertex Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Vertex. The board's role is to monitor Vertex Pharmaceuticals' management team and ensure that shareholders' interests are well served. Vertex Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Vertex Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| William Young, Independent Director | ||
| Jonathan JD, Executive Officer | ||
| Reshma Kewalramani, Executive Vice President - Global Medicines Development and Medical Affairs and Chief Medical Officer | ||
| Stephanie Franklin, Senior Officer | ||
| Michael Parini, Executive Vice President and Chief Legal Officer | ||
| Alan Garber, Independent Director | ||
| Joshua Boger, Executive Director and Chairman of Science and Technology Committee | ||
| Mike Tirozzi, SVP Officer | ||
| Damian Esq, Chief VP | ||
| Jeffrey MD, Executive Chairman | ||
| Nina Devlin, Senior Officer | ||
| MD FASN, President CEO | ||
| Stuart BSc, Executive COO | ||
| John Gray, Senior Vice President Genetic Therapies | ||
| Margaret McGlynn, Independent Director | ||
| Sangeeta Bhatia, Director | ||
| Kristen CPA, Senior Officer | ||
| Terrence Kearney, Independent Director | ||
| Ian Smith, CFO, Executive Vice President | ||
| Kristen Ambrose, Tax, Accounting | ||
| Paul Silva, Senior Vice President Corporate Controller | ||
| David Altshuler, Independent Director | ||
| Jeffrey Chodakewitz, Chief Medical Officer and Senior Vice President - Global Medicines Development | ||
| Elaine Ullian, Co-Lead Independent Director | ||
| Amit Sachdev, Senior Vice President - Global Government Strategy, Market Access and Value | ||
| David Greenway, Director | ||
| Charles Wagner, CFO, Executive Vice President | ||
| Ourania Tatsis, Ex Officer | ||
| Amit JD, Executive Officer | ||
| Bruce Sachs, Co-Lead Independent Director | ||
| Susie Lisa, Senior Relations | ||
| Lloyd Carney, Independent Director | ||
| Michael Partridge, Vice President - Investor Relations | ||
| Yuchun Lee, Independent Director | ||
| Kimberly White, Senior Vice President and Chief Communications Officer | ||
| Stuart Arbuckle, Chief Commercial Officer and Executive VP | ||
| Thomas Graney, CFO, Senior Vice President | ||
| Charles Milstein, Executive Vice President Chief Legal and Administrative Officer | ||
| Jeffrey Leiden, Chairman of the Board and Presidentident, CEO |
Vertex Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Vertex Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.23 | ||||
| Return On Asset | 0.13 | ||||
| Profit Margin | 0.37 % | ||||
| Operating Margin | 0.38 % | ||||
| Current Valuation | 92.23 B | ||||
| Shares Outstanding | 258.46 M | ||||
| Shares Owned By Insiders | 0.11 % | ||||
| Shares Owned By Institutions | 97.32 % | ||||
| Number Of Shares Shorted | 3.98 M | ||||
| Price To Earning | 24.57 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| LTC | Litecoin | |
| STETH | Staked Ether | |
| LINK | Chainlink |
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Vertex Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in estimate. For more information on how to buy Vertex Stock please use our How to Invest in Vertex Pharmaceuticals guide.You can also try the Piotroski F Score module to get Piotroski F Score based on the binary analysis strategy of nine different fundamentals.
Complementary Tools for Vertex Stock analysis
When running Vertex Pharmaceuticals' price analysis, check to measure Vertex Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vertex Pharmaceuticals is operating at the current time. Most of Vertex Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Vertex Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vertex Pharmaceuticals' price. Additionally, you may evaluate how the addition of Vertex Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |
Is Vertex Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Vertex Pharmaceuticals. If investors know Vertex will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Vertex Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 0.181 | Earnings Share 13.91 | Revenue Per Share 38.297 | Quarterly Revenue Growth 0.093 | Return On Assets 0.1317 |
The market value of Vertex Pharmaceuticals is measured differently than its book value, which is the value of Vertex that is recorded on the company's balance sheet. Investors also form their own opinion of Vertex Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Vertex Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Vertex Pharmaceuticals' market value can be influenced by many factors that don't directly affect Vertex Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Vertex Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Vertex Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Vertex Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.